Status:
COMPLETED
Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)
Lead Sponsor:
Oslo University Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
Phase:
NA
Brief Summary
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEM...
Detailed Description
Aprotinine (Trasylol) is a potent antifibrinolytic agent known to reduce bleeding after cardiac surgery. The most commeon practice is to give Trasylol in high doses immediately before surgery, during ...
Eligibility Criteria
Inclusion
- All coronary bypass operations in patients receiving Plavix within the last 7 days
Exclusion
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2007
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00257751
Start Date
March 1 2004
End Date
November 1 2007
Last Update
July 6 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.